Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Schering-Plough |
---|---|
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00034684 |
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.
Condition | Intervention | Phase |
---|---|---|
Leukemia Myelodysplastic Syndromes Leukemia, Myeloid, Chronic Blast Crisis Leukemia, Lymphocytic |
Drug: Farnesyl Protein Transferase Inhibitor |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety Study |
Official Title: | Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | P00701 |
Study First Received: | May 1, 2002 |
Last Updated: | May 31, 2006 |
ClinicalTrials.gov Identifier: | NCT00034684 |
Health Authority: | United States: Food and Drug Administration |
Leukemia Myelodysplastic Syndromes Leukemia, Myeloid Leukemia, Lymphocytic |
Myelodysplastic syndromes Blast Crisis Leukemia, Lymphoid Immunoproliferative Disorders Precancerous Conditions Hematologic Diseases Myelodysplasia Myelodysplastic Syndromes |
Myeloproliferative Disorders Leukemia, Myeloid Leukemia Lymphatic Diseases Preleukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Bone Marrow Diseases Lymphoproliferative Disorders |
Neoplastic Processes Neoplasms Disease Pathologic Processes |
Neoplasms by Histologic Type Immune System Diseases Syndrome Cell Transformation, Neoplastic |